HomeCompareSHPMY vs MAIN

SHPMY vs MAIN: Dividend Comparison 2026

SHPMY yields 3.82% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHPMY wins by $1365.76M in total portfolio value· pulled ahead in Year 6
10 years
SHPMY
SHPMY
● Live price
3.82%
Share price
$7.60
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1408.65M
Annual income
$1,341,128,296.97
Full SHPMY calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — SHPMY vs MAIN

📍 SHPMY pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHPMYMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHPMY + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHPMY pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHPMY
Annual income on $10K today (after 15% tax)
$324.34/yr
After 10yr DRIP, annual income (after tax)
$1,139,959,052.42/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, SHPMY beats the other by $1,109,513,456.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHPMY + MAIN for your $10,000?

SHPMY: 50%MAIN: 50%
100% MAIN50/50100% SHPMY
Portfolio after 10yr
$725.77M
Annual income
$688,473,322.49/yr
Blended yield
94.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

SHPMY
No analyst data
Altman Z
1.9
Piotroski
5/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHPMY buys
0
MAIN buys
0
No recent congressional trades found for SHPMY or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHPMYMAIN
Forward yield3.82%6.91%
Annual dividend / share$0.29$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%72.7%
Portfolio after 10y$1408.65M$42.89M
Annual income after 10y$1,341,128,296.97$35,818,348.00
Total dividends collected$1403.79M$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: SHPMY vs MAIN ($10,000, DRIP)

YearSHPMY PortfolioSHPMY Income/yrMAIN PortfolioMAIN Income/yrGap
1$11,463$763.16$12,434$1,193.51$971.00MAIN
2$13,901$1,635.18$16,255$2,280.05$2.4KMAIN
3$18,580$3,706.34$22,851$4,580.08$4.3KMAIN
4$29,141$9,259.81$35,577$9,892.59$6.4KMAIN
5$58,326$27,145.47$63,653$23,664.70$5.3KMAIN
6← crossover$163,965$101,556.29$136,601$65,054.52+$27.4KSHPMY
7$709,076$533,633.18$368,044$214,504.02+$341.0KSHPMY
8$5,072,218$4,313,507.31$1,301,668$887,987.40+$3.77MSHPMY
9$63,101,541$57,674,267.04$6,288,483$4,825,407.47+$56.81MSHPMY
10$1,408,646,945$1,341,128,296.97$42,886,603$35,818,348.00+$1365.76MSHPMY

SHPMY vs MAIN: Complete Analysis 2026

SHPMYStock

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

Full SHPMY Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this SHPMY vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHPMY vs SCHDSHPMY vs JEPISHPMY vs OSHPMY vs KOSHPMY vs ARCCSHPMY vs HTGCSHPMY vs GBDCSHPMY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.